📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. (2023)

First Author: Fisher JG

Attributed to: Targeting natural killer cell receptors for immunotherapeutic benefit funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41375-023-01984-z

PubMed Identifier: 37528310

Publication URI: http://europepmc.org/abstract/MED/37528310

Type: Journal Article/Review

Volume: 37

Parent Publication: Leukemia

Issue: 10

ISSN: 0887-6924